Posted by Michael Wonder on 31 Mar 2026
Praxis Precision Medicines announces FDA acceptance and priority review of new drug application for relutrigine in patients with SCN2A and SCN8A DEEs
30 March 2026 - Praxis Precision Medicines today announced that the US FDA has accepted for priority review its new drug application for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies.
The FDA has set a target action date under the PDUFA of 27 September 2026.
